ArticlePharmacoEconomics2021

Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.

Michael Dolph et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.